August 20, 2025Open Access

Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper

Ask AI

Bookmark

Authors

SLSamantha I. LiangParker Institute for Cancer Immunotherapy ZQZoe QuandtUniversity of California, San Francisco SWSara WienkeGuardant (United States)

Discussion

Member takes

Implication

Analysis reveals relationship between ctDNA tumor fraction and clinical benefit from immune checkpoint inhibitors across diverse cancers, suggesting potential for personalized therapy.

Key Points

Methylation-based ctDNA tumor fraction changes correlate with long-term clinical benefit from immune therapy.
Swimmer plots across cancer types highlight these changes as meaningful predictors of treatment response.
This observational analysis spans various cancer types, showcasing the relevance of ctDNA in predicting patient outcomes.
Findings imply potential for optimizing immune checkpoint inhibitor therapy based on ctDNA levels, supporting personalized cancer treatment approaches.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af750c7567bf4f94feddcf https://doi.org/10.1158/2767-9764.29948093

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals relationship between ctDNA tumor fraction and clinical benefit from immune checkpoint inhibitors across diverse cancers, suggesting potential for personalized therapy.

Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider